Table 5 Challenges in JIA treatment decisions
From: Understanding treatment decision making in juvenile idiopathic arthritis: a qualitative assessment
Sub-themes | Supporting quotations |
|---|---|
Limited long-term data | “They want to know long-term and as these biologics are coming up quicker and quicker, we don’t have some of that data yet and so I think that’s challenging for me.” Clinician 4 |
“…the unknowns about long-term use of these biologics … I think that factors in too, as far as any decision making that you have. That’s probably the biggest challenge.” Clinician 14 | |
When to stop treatment | “You’re really worried about whether when you taper, whether there’s going to be a worsening disease, whether you’ll be able to use the same medications and whether it will be just as effective.” Clinician 13 |
“One of the questions they always have also is when we stop this medicine which I think is harder to answer because I think we’re better in medicine, at starting medicines than stopping…” Clinician 11 | |
Health System Challenges | “I think expenses are a big [challenge], how costly the medication is.” Clinician 9 |
“…and trying to understand what would work best on them from a treatment standpoint as far as administering the medication, what their insurance may or may not pay for…” Clinician 3 |